{"success":true,"data":{"pressRelease":{"id":"20899","rtpr_id":"nBw2bL6CSa","ticker":"ABBV","exchange":"NYSE","all_tickers":["ABBV","LABP"],"title":"NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD","author":"Business Wire","published_at":"2026-05-05T12:00:01.598Z","article_body":"NImmune Biopharma Announces Presentations at Digestive Disease Week 2026\nSupporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily\nNIM-1324 for IBD\n\nNew data presented at DDW demonstrates that NIM-1324 outperforms current IBD\nmedications, establishes Phase 1 safety, tolerability and LANCL2 target\nengagement in humans\n\nSupports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral,\nonce-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease\n\nA well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000\nmg doses versus placebo to evaluate clinical remission and target engagement\nin ulcerative colitis patients\n\nNIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically\nvalidated to provide clinical remission in both ulcerative colitis and\nCrohn’s disease patients\n\nI&I oral therapeutic platform provides enhanced strategic capability\npositioning at the interface of immunity and metabolism across multiple\ninflammatory and autoimmune disease indications\n\nNImmune Biopharma (“NImmune”), a private, late-stage precision\ninflammation and immunology (“I&I”) biopharmaceutical company,\npresented two studies at Digestive Disease Week (DDW), which together\ndemonstrate that NIM-1324 meets all primary and secondary endpoints for the\ntreatment of IBD, successfully engages the LANCL2 target, shows an improved\npharmacokinetic (PK) profile, and possesses a favorable safety profile with no\ndose limiting toxicities.\n\nThe abstracts, titled “Safety, Tolerability and LANCL2 Target Engagement of\nNIM-1324 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study”\nand “NIM-1324: A Next-Generation LANCL2 Therapeutic Outperforms Current IBD\nMedications,” presented Phase 1 clinical data and preclinical evidence\nhighlighting NIM-1324’s safety, target engagement, and therapeutic potential\nin IBD. NIM‑1324 targets a dual LANCL2 mechanism that activates Tregs’\nanti-inflammatory actions and enhances mitochondrial metabolism. Given its\nimproved PK profile, NIM-1324 elicits its pharmacological actions by combining\ngut localized activity with systemic immunoregulatory effects via LANCL2\npathway activation to address symptoms both inside and outside the gut,\nincluding extraintestinal manifestations of disease.\n\n“DDW provided an important forum to share how NImmune and NIM-1324 have the\npotential to reshape the treatment paradigm for ulcerative colitis and\nCrohn’s disease,” said Dr. Josep Bassaganya‑Riera, Founder, Executive\nChairman, President and Chief Executive Officer of NImmune Biopharma. “The\nbreadth and consistency of the efficacy and safety data presented reinforce\nthe therapeutic promise of NIM-1324 in IBD and further validate our\necosystem-driven approach to translating novel scientific discoveries into\nclinically meaningful medicines. Beyond IBD, NIM-1324 has shown consistent\nsignals of therapeutic efficacy across lupus, rheumatoid arthritis, psoriasis,\nasthma, multiple sclerosis, Alzheimer’s disease, and Parkinson’s\ndisease—supporting its transformative pipeline-in-a-drug potential.”\n\nThe preclinical, translational and clinical findings presented at DDW\ndemonstrate that pharmacological activation of LANCL2 by NIM-1324 reprograms\nimmune cell metabolism to support durable immunoregulation through multiple\nsynergistic mechanisms of action. Research now demonstrates consistent and\npowerful signals of leading therapeutic efficacy through pharmacological\nactivation of the LANCL2 pathway across inflammatory bowel disease (IBD),\nNIM-1324’s lead indication, as well as follow on indications including\nlupus, psoriasis, rheumatoid arthritis, multiple sclerosis, Alzheimer’s\ndisease, Parkinson’s disease, and asthma. These critical findings further\nsupport the paradigm-shifting science, robust clinical validation and enormous\ncommercial potential of LANCL2 precision medicines.\n\n“The consistency of LANCL2 efficacy signals across disease models and\npatients continues to inform the development of NIM‑1324 while validating a\nsafe and effective broader immunoregulatory strategy grounded in a dual\ntargeted immunometabolic mechanism mediated through LANCL2, compared to the\nbroad and unsafe immune suppression typical of current IBD drugs, many of\nwhich have black box warnings due to significant adverse side effects,”\nadded Dr. Bassaganya‑Riera. “These findings highlight how our unique\nR&D ecosystem is working synergistically to expand our inflammation and\nimmunology (I&I) oral drug development platform and to accelerate the\nclinical development and commercialization of biomarker-driven LANCL2\nprecision medicines.”\n\nThe findings presented at DDW reflect more than two decades of sustained\nscientific collaboration led by Dr. Josep Bassaganya-Riera enabled by an\nI&I drug development platform that continues to generate new IP and\nprovides enhanced strategic capability positioning at the interface of\nimmunity and metabolism across multiple disease indications over the next few\ndecades. This burgeoning I&I BioHub comprises highly synergistic R&D\ncollaborations between NImmune, BioTherapeutics\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.biotherapeuticsinc.com%2F&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=BioTherapeutics&index=1&md5=76afb3b8942d7e4d9ac88dee74759bd4)\n, the NIMML Institute\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nimml.org%2F&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=NIMML+Institute&index=2&md5=b12473980fe69a577bee735e03aa1fc5)\n, and Dr. Bassaganya-Riera’s latest clinical program for the development of\nNIM-1324\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20260217742112%2Fen%2FLeading-the-Next-Wave-of-Innovative-IBD-Therapeutics-Targeting-Immunometabolism-Josep-Bassaganya-Riera-Launches-Clinical-Program-and-Business-Venture-to-Develop-NIM-1324-for-Ulcerative-Colitis-and-Crohns-disease&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=development+of+NIM-1324&index=3&md5=8ca44a08539fb5f13206a20826aac994)\n. This unique transdisciplinary model aligns discovery research, disease\nmodeling, biomarker development, and clinical translation, enabling assets\nsuch as NIM‑1324 to advance efficiently and cost-effectively from\nfundamental scientific discoveries through late‑stage clinical development\nand commercialization. This team and its innovative drug development ecosystem\nhave demonstrated significant clinical and commercial success\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nimml.org_news_detail_nimml-2Dinstitutes-2Dtitan-2Dx-2Da.i.-2Dpowered-2Dprecision-2Dmedicine-2Dplatform-2Dvalidated%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3D2FVmiY569kEpCncL_NhQ81YVv-gycQ4-OnPwLtbpaN4%26m%3D2aJ22nIQyH2z5TJ9Yj_e1DfWqWqcIQY-YnPjRBuSpTZbv6tYl1CEXPpzhGOkpApR%26s%3DbkPU2VYmAkZHY0A0MiSZ8gruQviHartA-JEJXqTBrsI%26e%3D&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=significant+clinical+and+commercial+success&index=4&md5=bf954c31d322cfb40afc10524f492543)\n, having enabled the foundation of Landos Biopharma in 2017, a company that\nDr. Bassaganya-Riera built from the ground up, took public (NASDAQ: LABP) in\n2021 and was acquired by AbbVie, Inc. (NYSE: ABBV) in May 2024.\n\nAbout NImmune Biopharma\n\nNImmune is a private late-stage precision inflammation and immunology\n(“I&I”) biopharmaceutical company that leverages a proprietary A.I.\nplatform to rapidly and capital efficiently develop novel best-in-class\nbiomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune\ndiseases. Underpinned by the TITAN-X computational platform that utilizes\nadvanced A.I., advanced computational modeling, and bioinformatics and\nbiomedical research capabilities to pioneer innovation in the development and\ncommercialization of novel best-in-class I&I therapies, NImmune’s\nbusiness model enables the rapid and capital-efficient clinical development of\nhigh conviction drug candidates to New Drug Application (NDA) filing and\ncommercialization. Additional information: www.NIMMUNEBIO.COM\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.NIMMUNEBIO.COM&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=www.NIMMUNEBIO.COM&index=5&md5=30894fa3aedb4e5837e222aa650d58a6)\n.\n\nAbout NIMML\n\nThe NIMML Institute is a 501(c)(3) non‑profit foundation dedicated to\ncombining advanced artificial intelligence–driven computational modeling\nwith translational research and clinical testing to accelerate development of\nthe next wave of precision medicines for inflammatory and autoimmune diseases.\nThe Institute applies its TITAN‑X™ advanced A.I.‑powered platform to\nlarge‑scale, transdisciplinary projects aimed at solving important public\nhealth challenges through precision immunology. The NIMML Institute is\nheadquartered in Blacksburg, Virginia.\n\nFor more information, please visit www.NIMML.org\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.NIMML.org&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=www.NIMML.org&index=6&md5=3f6a36e8ec1df35d1bcf65c8f140ac6e)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260505738752/en/\n(https://www.businesswire.com/news/home/20260505738752/en/)\n\nMedia Contact \n\nAlex Jeffrey / Jonathan Warren\n\nGasthalter & Co.\n\nnimmune@gasthalter.com \n(mailto:nimmune@gasthalter.com) \n212‑257‑4170\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw2bL6CSa","title":"NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD","author":"Business Wire","ticker":"ABBV","created":"2026-05-05T12:00:01.598Z","tickers":["ABBV","LABP"],"exchange":"NYSE","article_body":"NImmune Biopharma Announces Presentations at Digestive Disease Week 2026\nSupporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily\nNIM-1324 for IBD\n\nNew data presented at DDW demonstrates that NIM-1324 outperforms current IBD\nmedications, establishes Phase 1 safety, tolerability and LANCL2 target\nengagement in humans\n\nSupports the efficacy of NIM-1324, a de-risked, safe and well-tolerated, oral,\nonce-daily LANCL2 medicine for ulcerative colitis and Crohn’s disease\n\nA well-powered Phase 2 clinical trial of NIM-1324 will test 125, 250, and 1000\nmg doses versus placebo to evaluate clinical remission and target engagement\nin ulcerative colitis patients\n\nNIM-1324 novel mechanism of action—the LANCL2 pathway—is clinically\nvalidated to provide clinical remission in both ulcerative colitis and\nCrohn’s disease patients\n\nI&I oral therapeutic platform provides enhanced strategic capability\npositioning at the interface of immunity and metabolism across multiple\ninflammatory and autoimmune disease indications\n\nNImmune Biopharma (“NImmune”), a private, late-stage precision\ninflammation and immunology (“I&I”) biopharmaceutical company,\npresented two studies at Digestive Disease Week (DDW), which together\ndemonstrate that NIM-1324 meets all primary and secondary endpoints for the\ntreatment of IBD, successfully engages the LANCL2 target, shows an improved\npharmacokinetic (PK) profile, and possesses a favorable safety profile with no\ndose limiting toxicities.\n\nThe abstracts, titled “Safety, Tolerability and LANCL2 Target Engagement of\nNIM-1324 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study”\nand “NIM-1324: A Next-Generation LANCL2 Therapeutic Outperforms Current IBD\nMedications,” presented Phase 1 clinical data and preclinical evidence\nhighlighting NIM-1324’s safety, target engagement, and therapeutic potential\nin IBD. NIM‑1324 targets a dual LANCL2 mechanism that activates Tregs’\nanti-inflammatory actions and enhances mitochondrial metabolism. Given its\nimproved PK profile, NIM-1324 elicits its pharmacological actions by combining\ngut localized activity with systemic immunoregulatory effects via LANCL2\npathway activation to address symptoms both inside and outside the gut,\nincluding extraintestinal manifestations of disease.\n\n“DDW provided an important forum to share how NImmune and NIM-1324 have the\npotential to reshape the treatment paradigm for ulcerative colitis and\nCrohn’s disease,” said Dr. Josep Bassaganya‑Riera, Founder, Executive\nChairman, President and Chief Executive Officer of NImmune Biopharma. “The\nbreadth and consistency of the efficacy and safety data presented reinforce\nthe therapeutic promise of NIM-1324 in IBD and further validate our\necosystem-driven approach to translating novel scientific discoveries into\nclinically meaningful medicines. Beyond IBD, NIM-1324 has shown consistent\nsignals of therapeutic efficacy across lupus, rheumatoid arthritis, psoriasis,\nasthma, multiple sclerosis, Alzheimer’s disease, and Parkinson’s\ndisease—supporting its transformative pipeline-in-a-drug potential.”\n\nThe preclinical, translational and clinical findings presented at DDW\ndemonstrate that pharmacological activation of LANCL2 by NIM-1324 reprograms\nimmune cell metabolism to support durable immunoregulation through multiple\nsynergistic mechanisms of action. Research now demonstrates consistent and\npowerful signals of leading therapeutic efficacy through pharmacological\nactivation of the LANCL2 pathway across inflammatory bowel disease (IBD),\nNIM-1324’s lead indication, as well as follow on indications including\nlupus, psoriasis, rheumatoid arthritis, multiple sclerosis, Alzheimer’s\ndisease, Parkinson’s disease, and asthma. These critical findings further\nsupport the paradigm-shifting science, robust clinical validation and enormous\ncommercial potential of LANCL2 precision medicines.\n\n“The consistency of LANCL2 efficacy signals across disease models and\npatients continues to inform the development of NIM‑1324 while validating a\nsafe and effective broader immunoregulatory strategy grounded in a dual\ntargeted immunometabolic mechanism mediated through LANCL2, compared to the\nbroad and unsafe immune suppression typical of current IBD drugs, many of\nwhich have black box warnings due to significant adverse side effects,”\nadded Dr. Bassaganya‑Riera. “These findings highlight how our unique\nR&D ecosystem is working synergistically to expand our inflammation and\nimmunology (I&I) oral drug development platform and to accelerate the\nclinical development and commercialization of biomarker-driven LANCL2\nprecision medicines.”\n\nThe findings presented at DDW reflect more than two decades of sustained\nscientific collaboration led by Dr. Josep Bassaganya-Riera enabled by an\nI&I drug development platform that continues to generate new IP and\nprovides enhanced strategic capability positioning at the interface of\nimmunity and metabolism across multiple disease indications over the next few\ndecades. This burgeoning I&I BioHub comprises highly synergistic R&D\ncollaborations between NImmune, BioTherapeutics\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.biotherapeuticsinc.com%2F&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=BioTherapeutics&index=1&md5=76afb3b8942d7e4d9ac88dee74759bd4)\n, the NIMML Institute\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nimml.org%2F&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=NIMML+Institute&index=2&md5=b12473980fe69a577bee735e03aa1fc5)\n, and Dr. Bassaganya-Riera’s latest clinical program for the development of\nNIM-1324\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20260217742112%2Fen%2FLeading-the-Next-Wave-of-Innovative-IBD-Therapeutics-Targeting-Immunometabolism-Josep-Bassaganya-Riera-Launches-Clinical-Program-and-Business-Venture-to-Develop-NIM-1324-for-Ulcerative-Colitis-and-Crohns-disease&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=development+of+NIM-1324&index=3&md5=8ca44a08539fb5f13206a20826aac994)\n. This unique transdisciplinary model aligns discovery research, disease\nmodeling, biomarker development, and clinical translation, enabling assets\nsuch as NIM‑1324 to advance efficiently and cost-effectively from\nfundamental scientific discoveries through late‑stage clinical development\nand commercialization. This team and its innovative drug development ecosystem\nhave demonstrated significant clinical and commercial success\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nimml.org_news_detail_nimml-2Dinstitutes-2Dtitan-2Dx-2Da.i.-2Dpowered-2Dprecision-2Dmedicine-2Dplatform-2Dvalidated%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3D2FVmiY569kEpCncL_NhQ81YVv-gycQ4-OnPwLtbpaN4%26m%3D2aJ22nIQyH2z5TJ9Yj_e1DfWqWqcIQY-YnPjRBuSpTZbv6tYl1CEXPpzhGOkpApR%26s%3DbkPU2VYmAkZHY0A0MiSZ8gruQviHartA-JEJXqTBrsI%26e%3D&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=significant+clinical+and+commercial+success&index=4&md5=bf954c31d322cfb40afc10524f492543)\n, having enabled the foundation of Landos Biopharma in 2017, a company that\nDr. Bassaganya-Riera built from the ground up, took public (NASDAQ: LABP) in\n2021 and was acquired by AbbVie, Inc. (NYSE: ABBV) in May 2024.\n\nAbout NImmune Biopharma\n\nNImmune is a private late-stage precision inflammation and immunology\n(“I&I”) biopharmaceutical company that leverages a proprietary A.I.\nplatform to rapidly and capital efficiently develop novel best-in-class\nbiomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune\ndiseases. Underpinned by the TITAN-X computational platform that utilizes\nadvanced A.I., advanced computational modeling, and bioinformatics and\nbiomedical research capabilities to pioneer innovation in the development and\ncommercialization of novel best-in-class I&I therapies, NImmune’s\nbusiness model enables the rapid and capital-efficient clinical development of\nhigh conviction drug candidates to New Drug Application (NDA) filing and\ncommercialization. Additional information: www.NIMMUNEBIO.COM\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.NIMMUNEBIO.COM&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=www.NIMMUNEBIO.COM&index=5&md5=30894fa3aedb4e5837e222aa650d58a6)\n.\n\nAbout NIMML\n\nThe NIMML Institute is a 501(c)(3) non‑profit foundation dedicated to\ncombining advanced artificial intelligence–driven computational modeling\nwith translational research and clinical testing to accelerate development of\nthe next wave of precision medicines for inflammatory and autoimmune diseases.\nThe Institute applies its TITAN‑X™ advanced A.I.‑powered platform to\nlarge‑scale, transdisciplinary projects aimed at solving important public\nhealth challenges through precision immunology. The NIMML Institute is\nheadquartered in Blacksburg, Virginia.\n\nFor more information, please visit www.NIMML.org\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.NIMML.org&esheet=54528860&newsitemid=20260505738752&lan=en-US&anchor=www.NIMML.org&index=6&md5=3f6a36e8ec1df35d1bcf65c8f140ac6e)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260505738752/en/\n(https://www.businesswire.com/news/home/20260505738752/en/)\n\nMedia Contact \n\nAlex Jeffrey / Jonathan Warren\n\nGasthalter & Co.\n\nnimmune@gasthalter.com \n(mailto:nimmune@gasthalter.com) \n212‑257‑4170\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-05T12:00:01.728304229Z","server_sent_at_ms":1777982401728},"received_at":"2026-05-05T12:00:01.783Z","source_url":"https://www.businesswire.com/news/home/20260505738752/en/"},"analysis":{"id":"17472","press_release_id":"20899","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"NImmune Biopharma presented Phase 1 data at Digestive Disease Week 2026 demonstrating that NIM-1324 met safety and tolerability endpoints while engaging the LANCL2 target in humans.\n\nThe company plans a Phase 2 trial testing 125 mg, 250 mg, and 1000 mg doses versus placebo to evaluate clinical remission in ulcerative colitis patients.\n\nThe release notes that NImmune’s founder previously established Landos Biopharma, a company acquired by AbbVie in May 2024.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Private biotech data release; ABBV connection historical only."},"keyFigures":{"drugName":"NIM-1324","phaseOfTrial":"Phase 1","customDimensions":{"indication":"ulcerative colitis and Crohn’s disease","planned_phase_2_doses":"125, 250, and 1000 mg"}},"quotedText":"DDW provided an important forum to share how NImmune and NIM-1324 have the potential to reshape the treatment paradigm for ulcerative colitis and Crohn’s disease","namedEntities":{"people":[{"name":"Dr. Josep Bassaganya-Riera","role":"Founder, Executive Chairman, President and Chief Executive Officer of NImmune Biopharma"},{"name":"Alex Jeffrey","role":"Media Contact"},{"name":"Jonathan Warren","role":"Media Contact"}],"products":["NIM-1324","LANCL2 pathway","TITAN-X"],"companies":[{"name":"NImmune Biopharma","relationship":"subject"},{"name":"AbbVie, Inc.","ticker":"ABBV","relationship":"acquirer (of Landos Biopharma)"},{"name":"Landos Biopharma","ticker":"LABP","relationship":"acquired (by AbbVie)"},{"name":"BioTherapeutics","relationship":"partner"},{"name":"NIMML Institute","relationship":"partner"},{"name":"Gasthalter & Co.","relationship":"PR firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"The press release concerns NImmune Biopharma's clinical data and pipeline, not AbbVie's. AbbVie is mentioned only in the context of having acquired the founder's previous company in 2024, representing no material impact on AbbVie's current operations."},"tickerRelevance":{"others":[{"ticker":"LABP","relevance":"mentioned"}],"primary":"ABBV"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"Mega Cap","eventGravity":"private_company_data","issuerAuthored":false}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"NImmune Biopharma presented Phase 1 data at Digestive Disease Week 2026 demonstrating that NIM-1324 met safety and tolerability endpoints while engaging the LANCL2 target in humans.\n\nThe company plans a Phase 2 trial testing 125 mg, 250 mg, and 1000 mg doses versus placebo to evaluate clinical remission in ulcerative colitis patients.\n\nThe release notes that NImmune’s founder previously established Landos Biopharma, a company acquired by AbbVie in May 2024.","key_figures":{"drugName":"NIM-1324","phaseOfTrial":"Phase 1","customDimensions":{"indication":"ulcerative colitis and Crohn’s disease","planned_phase_2_doses":"125, 250, and 1000 mg"}},"named_entities":{"people":[{"name":"Dr. Josep Bassaganya-Riera","role":"Founder, Executive Chairman, President and Chief Executive Officer of NImmune Biopharma"},{"name":"Alex Jeffrey","role":"Media Contact"},{"name":"Jonathan Warren","role":"Media Contact"}],"products":["NIM-1324","LANCL2 pathway","TITAN-X"],"companies":[{"name":"NImmune Biopharma","relationship":"subject"},{"name":"AbbVie, Inc.","ticker":"ABBV","relationship":"acquirer (of Landos Biopharma)"},{"name":"Landos Biopharma","ticker":"LABP","relationship":"acquired (by AbbVie)"},{"name":"BioTherapeutics","relationship":"partner"},{"name":"NIMML Institute","relationship":"partner"},{"name":"Gasthalter & Co.","relationship":"PR firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:6c7fa2f5e3b62e83","schema_hash":"sha256:ee8f711bc9bfba0d","created_at":"2026-05-06T18:27:31.478Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"Mega Cap","eventGravity":"private_company_data","issuerAuthored":false}},"durationMs":null,"modelName":"glm-4.7"}}